WayPoint Biomedical Receives Strong Upgrade by Respected Research Firm; $7.5 Million Secured for New Medical Records Joint Vent
2006年4月5日 - 9:00PM
ビジネスワイヤ(英語)
WayPoint Biomedical, Inc. (Other OTC: WYPH.PK) is pleased to
announce a well-respected firm, TRI-STATE Capital (TSC), has
upgraded their equity rating on WYPH. This strong upgrade comes at
a time when the company is preparing to launch their new high
demand Hangover Free topical patch and further expand the US launch
of their drink spiking detection kit range. The strong upgrade is
also due to WayPoint management securing $7.5 million in initial
capital to manufacture, market, and distribute their new JV's
SmartCard-based Electronic Medical Records healthcare technology on
a global scale. WayPoint CEO, Dennis Shepherd, states, "We are
honored to have a quality independent research firm review our
overall operations, progress and to provide the resulting upgrade
in our stock. This offers further confirmation to our shareholders
that our company is headed in the right direction". Mr. Shepherd
further comments, "Our upcoming Hangover Free Topical Patch has the
potential to quickly generate several million dollars of sales and
we anticipate a strong revenue surge from our Drink Detective(TM)
drink spiking detection range through our Las Vegas, NV
introduction. Las Vegas is a playground for sexual predators and
thieves who use these now detectable drugs to perpetuate their
crimes. We are introducing both a product and an
education/awareness campaign that can help stop this crime."
WayPoint has already received orders from two key Canadian Retail
Pharmacy groups for their drink spiking detection kit. The company
has also confirmed requests for over 10,000 units to be distributed
throughout Las Vegas hotels, bars, clubs, nightclubs, and retail
stores. Management anticipates accelerated growth throughout 2006
and 2007 due to a robust product pipeline of innovative new
products, aggressive marketing, and worldwide expansion. TSC is
noted for their work with, account executives, analysts, portfolio
managers, institutions, venture capital investors, individual
investors and the media. To view the entire independent research
report, please click on the attached URL: http://www.otclive.com
About WayPoint Biomedical, Inc. WayPoint Biomedical, Inc., a wholly
owned subsidiary of WayPoint Biomedical Holdings, Inc. (Other
OTC:WYPH), is an innovative biomedical technology firm,
specializing in diagnostic tests and devices for screening and
monitoring human health, fitness and environment. The Company
develops and markets cutting-edge disposable rapid tests that offer
both a preliminary diagnostic screen to specific conditions, along
with a future path for consumers, medical providers, and first
responders to follow regarding their health status or environmental
condition. For more information on WayPoint Biomedical visit
www.waypointbiomedical.com, www.drinkdetectiveusa.com.
Forward-Looking Statements This press release contains
forward-looking statements. By their nature, forward-looking
statements and forecasts involve risks and uncertainties because
they relate to events and depend on circumstances that will occur
in the near future. There are a number of factors that could cause
actual results and developments to differ materially.
Waypoint Biomedical (CE) (USOTC:WYPH)
過去 株価チャート
から 11 2024 まで 12 2024
Waypoint Biomedical (CE) (USOTC:WYPH)
過去 株価チャート
から 12 2023 まで 12 2024
Real-Time news about Waypoint Biomedical Holdings Inc (CE) (その他OTC): 0 recent articles
その他のWayPoint Biomedical, Inc.ニュース記事